Table 6.
P-NET results: [177Lu]Lu-DOTA-TATE versus SoC, [177Lu]Lu-DOTA-TATE versus everolimus, [177Lu]Lu-DOTA-TATE versus sunitinib.
| Treatment modalities | Costs | QALYs | Incremental costs | Incremental QALYs | ICER (cost/QALY) | P (cost-effective) at WTP £30,000 |
|---|---|---|---|---|---|---|
| SoC (RADIANT-3) | £60,326 | 3.12 | ||||
| [177Lu]Lu-DOTA-TATE | £111,289 | 4.94 | £50,963 (€53,169) | 1.82 | £28,038 (€29,251) | 65% |
| SoC (NCT00428597) | £53,033 | 2.96 | ||||
| [177Lu]Lu-DOTA-TATE | £118,525 | 5.64 | £65,491 (€68,315) | 2.96 | £22,146 (€23,101) | 99% |
| Everolimus | £72,497 | 3.25 | ||||
| [177Lu]Lu-DOTA-TATE | £113,103 | 5.11 | £40,606 (€42,352) | 1.86 | £21,827 (€22,766) | 96% |
| Sunitinib | £81,350 | 3.55 | ||||
| [177Lu]Lu-DOTA-TATE | £117,915 | 5.87 | £36,617 (€38,135) | 2.32 | £15,768 (€16,445) | 100% |
GI-NETs, neuroendocrine tumours located in the gastrointestinal tract; P-NETs, neuroendocrine tumours located in the pancreas; QALYs, quality-adjusted life-years.
P stands for probability, SoC for standard of care and WTP for Willingness to Pay.